Short-Course Rifamycin-Based Regimens Preferred for Latent TB

FRIDAY, Feb. 14, 2020 -- For treatment of latent tuberculosis infection (LTBI), short-course rifamycin-based regimens are preferred over longer-course isoniazid monotherapy, according to guidelines published in the Feb. 14 issue of the U.S. Centers...
Source: Drugs.com - Pharma News - Category: Pharmaceuticals Source Type: news